

VU Research Portal

Proteasome inhibitors in acute leukemia

Niewerth, D.

2014

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Niewerth, D. (2014). *Proteasome inhibitors in acute leukemia*. [, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Contents

Chapter 1	General introduction and introduction to the chapters	9
Chapter 2	Proteasome inhibitors in acute leukemia <i>Exp Rev Anticancer Ther 2013 Mar;13(3):327-37</i>	19
Chapter 3	Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells <i>Leukemia 2012 Apr;26(4):757-68</i>	39
Chapter 4	Antileukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924 <i>Biochem Pharmacol 2014 May 1;89(1):43-51</i>	63
Chapter 5	Antileukemic activity and molecular mechanism of drug resistance to the marine <i>Salinospora tropica</i> proteasome inhibitor salinosporamide A (Marizomib) <i>Mol. Pharmacol 2014 Jul;86(1):12-9</i>	81
Chapter 6	Interferon- γ -induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines <i>J Hematol Oncol. 2014 Jan 13;7(1):7</i>	99
Chapter 7	Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. <i>Haematologica 2013;98: 1896–1904.</i>	127
Chapter 8	Ratios of immunoproteasome over constitutive proteasome expression is an indicator for sensitivity to bortezomib-containing reinduction chemotherapy in relapsed pediatric acute leukemia patients <i>Manuscript in preparation</i>	151
Chapter 9	General discussion and future perspectives	165
Chapter 10	Summary / Samenvatting	179
	List of publications	191
	Curriculum vitae	193
	Dankwoord	195